Oncology Brothers: Practice-Changing Cancer Discussions

In this informative episode we dived into the world of CAR T-cell therapies for multiple myeloma. In this ToxCheck episode, we focused on the available CAR-T options, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and discussed their side effects, management strategies, and the importance of patient education.
 
We were joined by myeloma specialists Caitlin Costello, MD, from UC San Diego Health, and Joshua Richter, MD, from Mount Sinai, who shared their insights on the acute and chronic side effects associated with CAR-T therapies. Learn about the common toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), as well as the role of prophylactic treatments and the importance of bridging therapy.
 
This episode emphasized the critical collaboration between community oncologists and academic institutions to ensure patients receive the best care possible. Tune in to understand how to navigate the complexities of CAR-T therapies and empower your patients with the knowledge they need.
 
Key Topics:
Overview of CAR-T therapies for multiple myeloma
Common side effects: CRS and ICANS
Management strategies for acute and chronic toxicities
The role of prophylactic treatments
Importance of communication between community and academic oncologists
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#CARTtherapy, #MultipleMyeloma, #CRS, #ICANS, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of treating multiple myeloma, focusing on two challenging cases from the community. Joined by experts Marco Davila, MD PhD, from Roswell Park Comprehensive Cancer Center and Krina Patel, MD MSc, from MD Anderson Cancer Center, they discuss the nuances of treatment options for patients experiencing disease relapse post-transplant and disease progression while on maintenance therapy.
 
Key topics included:
The importance of thorough workup and repeat cytogenetics in high-risk multiple myeloma patients
The debate between CAR T-cell therapy and bispecific antibodies as treatment options
Strategies for managing patients with comorbidities and the role of shared decision-making in treatment planning
Insights into the side effects associated with CAR-T and bispecific therapies, including infection risks and neurological symptoms
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
Join us as we explored the latest advancements in multiple myeloma treatment and the exciting potential for achieving long-term remission and even cure in select patient populations.
 
Don't forget to like, subscribe, and hit the notification bell for more insightful discussions on oncology!
#MultipleMyeloma, #CARTtherapy, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers
 

Join the Oncology Brothers, in this insightful episode as they dive deep into the treatment algorithms for newly diagnosed multiple myeloma and smoldering myeloma. Featuring Gurbakhash Kaur, MD, a myeloma specialist from the Mount Sinai Hospital, the discussion covered the latest advancements in treatment options, including the recent approval of daratumumab for high-risk smoldering myeloma and the evolving landscape of frontline therapies.
 
In this episode, you'll learn about:
The definition of high-risk smoldering myeloma and the criteria for treatment versus active surveillance
The current treatment paradigms for newly diagnosed multiple myeloma, including the importance of quadruple therapy
Insights into managing frail patients and the considerations for transplant eligibility
The role of minimal residual disease (MRD) assessments in treatment decisions and maintenance therapy
The impact of cytopenias and how to manage them effectively
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the complexities of treating multiple myeloma. Don't miss out on this informative discussion!
#MultipleMyeloma, #SmolderingMyeloma, #HemeMalignancy, #MRD, #OncologyBrothers
 

Welcome back to the Oncology Brothers podcast! In this episode, we dived into the latest highlights from the EHA 2026 conference, focusing on groundbreaking studies in the leukemia space.
Join us as we welcome Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center to discuss three pivotal studies:
OPTI-AML: explored the findings on the use of venetoclax in combination with azacitidine for newly diagnosed AML patients, comparing 14-day versus 28-day treatment regimens and their impact on cytopenias and overall outcomes.
KOMET-007: promising early data on menin inhibitors, specifically Ziftomenib, in frontline settings for patients with NPM1 and KMT2A rearrangements, and how it may change the landscape of AML treatment.
SENTRY: analyzed the combination of ruxolitinib and selinexor for myelofibrosis, discussing its effects on spleen volume reduction and overall survival, as well as the implications of side effects.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
Tune in for an insightful discussion on the future of leukemia treatment and the importance of genetic markers in therapy decisions. Don't forget to like, subscribe, and check out our other conference highlights from ASCO and EHA!
#EHA2026, #Leukemia, #AML, #Myelofibrosis, #OncologyBrothers
 

In this episode of the Oncology Brothers podcast, we tackled two real-world challenging cases in diffuse large B-cell lymphoma (DLBCL) alongside two lymphoma experts — Dr. Matthew Lunning from the University of Nebraska and Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. The central question: when faced with relapsed or transformed aggressive B-cell lymphoma, how do you choose between CAR-T cell therapy and bispecific antibodies, and how do you get patients through this safely?
 
Key topics discussed included:
The role of CAR-T cell therapy in early relapsed DLBCL based on ZUMA-7 and TRANSFORM trial data, and practical strategies for bridging and holding therapy pre- and post-apheresis to safely deliver treatment.
A comparison of axicabtagene ciloleucel versus lisocabtagene maraleucel in terms of efficacy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) rates, and outpatient feasibility.
Management of transformed follicular lymphoma to double-hit DLBCL in the third-line setting, including the role of glofitamab, mosunetuzumab, polatuzumab, and epcoritamab as bridges to CAR-T cell therapy.
The importance of early partnership between community oncologists and tertiary care centers to ensure patients access CAR-T and bispecific therapies in a timely manner.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Join us for this expert discussion on navigating the complex treatment landscape of relapsed and transformed aggressive B-cell lymphoma. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!
#DLBCL, #CARTTherapy, #BispecificAntibodies, #Hematology, #OncologyBrothers
 

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Carla Casulo, a world-renowned clinician and researcher from the University of Rochester, to discuss the latest highlights from the European Hematology Association (EHA) 2026 conference, focusing on lymphoma.
 
Join us as we dived into four pivotal studies:
frontMIND: We explored the efficacy of tafasitamab plus lenalidomide with R-CHOP compared to R-CHOP alone in frontline treatment for diffuse large B-cell lymphoma (DLBCL). Discover the implications of improved progression-free survival (PFS) and the associated toxicities.
POLAR-BEAR: We discussed the head-to-head comparison of mini–pola-R-CHP versus mini–R-CHOP in frail or elderly patients with DLBCL. What does this mean for the use of polatuzumab in clinical practice?
High-Dose Methotrexate for CNS Prophylaxis: Learn about the significant findings that suggest high-dose methotrexate may not improve outcomes in high-risk patients, potentially changing treatment protocols.
EPCOR FL1: We covered the approval of epcoritamab in relapsed and refractory follicular lymphoma, highlighting its benefits and the importance of time-limited therapy.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
Tune in for an insightful discussion on these important studies and their potential impact on clinical practice.
Don't forget to subscribe for more updates on conference highlights, FDA approvals, and treatment algorithms!

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approvals for sacituzumab govitecan in frontline settings for metastatic triple-negative breast cancer. Joined by Dr. Sara Tolaney, a breast medical oncologist from the Dana-Farber Cancer Institute, we discussed the exciting developments in breast cancer treatment, with ASCENT-03 and ASCENT-04 trials.
 
Key topics covered in this episode include:
Overview of the recent FDA approvals for antibody-drug conjugates (ADCs) in breast cancer
Detailed discussion on the ASCENT-04 trial focusing on PD-L1–positive metastatic triple-negative breast cancer
Insights into the ASCENT-03 trial for PD-L1–negative disease
Comparison of sacituzumab govitecan and datopotamab deruxtecan (Dato-DXd), including their efficacy and side effect profiles
Management strategies for common side effects such as neutropenia and diarrhea
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Join us as we explored the evolving landscape of breast cancer treatment and the importance of shared decision-making in patient care. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#TripleNegativeBreastCancer, #Sacituzumab, #ASCENT03, #ASCENT04, #OncologyBrothers

In this ASCO 2026 Highlights discussion we dived into the latest advancements in breast cancer space. In this episode, we welcomed back Dr. Hope Rugo to discuss key studies that are shaping the future of breast cancer treatment.
 
Episode Highlights:
OPTIMA: Discover how the Prosigna genomic assay could change the approach to adjuvant chemotherapy in hormone receptor-positive breast cancer.
lidERA Update: Learn about the promising results of giredestrant, an oral SERD, and its potential role in adjuvant settings.
VIKTORIA-1: Exploring the implications of gedatolisib for PIK3CA mutated disease and its impact on progression-free survival.
Triple Negative Breast Cancer: Insights on the final overall survival updates from the KEYNOTE-522 and the exciting developments in antibody-drug conjugates (ADCs) like sasitizumab through ASCENT-03 and ASCENT-04 studies, and datopotamab from TROPION-Breast02 study.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
 
Follow us on social media:
⁠ ⁠X/Twitter: https://x.com/oncbrothers
⁠ ⁠Instagram: https://www.instagram.com/oncbrothers
⁠ Website: https://oncbrothers.com/
 
Hope this episode provided the very needed updates from ASCO 2026 focusing on the breast cancer world. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
 
#BreastCancer #ASCO2026 #ClinicalTrials #PrecisionOncology #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rahul Banerjee, a myeloma specialist from the Fred Hutch Cancer Center, to discuss the latest updates in multiple myeloma from EHA 2026.
 
Join us as we dived into:
The CEPHEUS study update, reaffirming the standard of care with quadruple therapy upfront, specifically D-VRd
Insights on the efficacy of teclistamab in early relapse refractory settings, including updates from the MajesTEC-3 and MajesTEC-9 studies.
The promising data around talquetamab from the MonumenTAL-3 study, highlighting its significant progression-free survival (PFS) improvement.
An overview of mezigdomide, a new immunomodulatory agent, and its impact on treatment strategies for anti-CD38 and lenalidomide-refractory patients.
 
We emphasized the importance of managing side effects and optimizing treatment sequences to ensure our patients can stay on these innovative therapies longer and safely.
 
Tune in for an informative discussion packed with the latest research and clinical insights in the world of oncology!
 
Listen to us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
 
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#MultipleMyeloma, #EHA2026, #BispecificAntibodies, #CELMoDs, #OncologyBrothers
 

We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents.
 
Discover the current treatment algorithms for relapsed multiple myeloma, including the role of triplet therapies, the significance of the MajesTEC-3 and MajesTEC-9 studies, and the clinical implications of new data. The discussion also covered the importance of managing side effects, the necessity of collaboration between community oncologists and academic centers, and the future of treatment in this dynamic field.
 
Whether you're a healthcare professional or someone interested in the latest in cancer treatment, this episode provides valuable insights into the future of multiple myeloma therapy.
 
Topics Covered:
Current treatment options for relapsed multiple myeloma
Insights from the MajesTEC-3 and MajesTEC-9 studies
The role of bispecific antibodies and CAR-T therapies
Managing side effects and patient care strategies
The importance of community and academic partnerships
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
 
Tune in now and stay informed about the latest in oncology!
#MultipleMyeloma, #BispecificAntibody, #CARTtherapy, #CELMoDs, #OncologyBrothers